(203) 306-3336

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX-0105

Inventors:

Ali et al.

Serial No.:

09/700,700

Filing Date:

November 20, 2000

Examiner:

Davis, Minh Tam B.

Group Art Unit:

1642

Title:

A Novel Method of Diagnosing,

Monitoring, and Staging Prostate Cancer

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450

On this date: April 5, 2004

Kathleen A. Tyrrell/Registration No. 38,350

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

() In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

.04/19/2004 SLUANG1 00000006 501619 09700700

01 FC:1806

180.00 DA

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- (XX) In accordance with §1.97(c), this Information Disclosure

 Statement is being filed after the period set forth in

 §1.97(b) above but before the mailing date of either a Final

 Action under §1.113 or a Notice of Allowance under §1.311,

 therefore:
 - () Certification in Accordance with §1.97(e) is attached hereto; or
 - (XX) Authorization to charge Deposit Account No. 50-1616 the fee of \$180.00 as set forth in \$1.17(p) is provided.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _______, filed ________, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- (XX) All listed references are in the English language.

Respectfully submitted,

Kat/hleen A. Tyrrell

Registration No. 38,350

Date: <u>April 5, 2004</u>

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No. DEX-0105

Serial No. **09/700,700**

Sheet 01 of 02

Applicant

Ali et al.

Group

Filing Date
November 20, 2000

1642

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	CA-	2002/0022248	2-21-02	Xu et al.	435	69.1
						•
				*		
	,					
				·	• 4	
	i ·					
	.,		4	. *		

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Transla YES	tion NC
	СВ	WO 00/04149	27-1-00	PCT	x	
	CC	WO 99/64594	16-12-99	PCT	х	

EXAMINER

DATE CONSIDERED



Form F10 1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.	Serial No. 09/700,700

Applicant Ali et al.

Filing Date Group
November 20, 2000 1642

OTHER DOO	UMEN	TS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	DA	DA Abate-Shen et al., "Nkx3.1; Pten Mutant Mice Develop Invasive Prostate Adenocarcinoma and Lymph Node Metastases1", Cancer Research 2003 63(14):3886-3890						
	DB	Bierberich et al., "Prostate-specific and Androgen- dependent Expression of a Novel Homeobox Gene", J. Biol. Chem. 1996 271(50):31779-31782 reprinted as pages 1-10						
1 .	DC	He et al., "A Novel Human Prostate-Specific, Androgen-Regulated Homeobox Gene (NKX3.1) That Maps to 8p21, a Region Frequently Deleted in Prostate Cancer", Genomics 1997 43:69-77						
	DD	Herbrand et al., "Transcription factors Nkx3.1 and Nkx3.2 (Bapx1) play an overlapping role in sclerotomal development of the mouse", Mechanisms of Development 2002 117:217-224						
	DE Kim et al., "Nkx3.1 Mutant Mice Recapitulate Early Stages of Prostate Carcinogenesis1", Cancer Research 2002 62:2999-3004							
	DF	Kim et al., "Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis", Proc. Natl. Acad. Sci. USA 2002 99(5):2884-2889 reprinted as pages 1-10						
	DG	Prescott et al., "Isolation and Androgen Regulation of the Human Homeobox cDNA, NKX3.1", The Prostate 1998 35:71-80						
	DH	Sciavolino et al., "Tissue-Specific Expression of Murine $Nkx3.1$ in the Male Urogenital System", Developmental Dynamics 1997 209:127-138						
.,,	DI	NCBI Genbank Accession U80669 [gi:1732377] 10 December 1996 - 3 June 1999 with Revision History						
EXAMINER		DATE CONSIDERED						



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

trorney Docket No.:

DEX-0105

Inventors:

Ali et al.

Serial No.:

09/700,700

Filing Date:

November 20, 2000

Examiner:

Davis, Minh Tam B.

Group Art Unit:

1642

Title:

A Novel Method of Diagnosing,

Monitoring, and Staging Prostate Cancer

I, **Kathleen A. Tyrrell**, Registration No. **38,350**, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450

On this date: April 5, 2004

Kathleen A. Tyrrell/Registration No. 38,350

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

() In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three months of the filing date of the above-identified

04/19/2004 SLUANG1 00000006 09700700

01 FC:1806

180.00 DA

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- (XX) In accordance with §1.97(c), this Information Disclosure
 Statement is being filed after the period set forth in
 §1.97(b) above but before the mailing date of either a Final
 Action under §1.113 or a Notice of Allowance under §1.311,
 therefore:
 - () Certification in Accordance with §1.97(e) is attached hereto; or
 - (XX) Authorization to charge Deposit Account No. 50-1616 the fee of \$180.00 as set forth in \$1.17(p) is provided.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. ______, filed ______, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- (XX) All listed references are in the English language.

Respectfully submitted,

Kathleen A. Tyrrell Registration No. 38,35

Date: April 5, 2004

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Filing Date Group November 20, 2000 1642

U. S. PATENT DOCUMENTS

Examiner Initial		Document	Date	Name	Class	Subclass
	CA	2002/0022248	2-21-02	Xu et al.	435	69.1

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Transla YES	Translation YES NO	
	СВ	WO 00/04149	27-1-00	PCT	x		
	CC	WO 99/64594	16-12-99	PCT	x		
						•	
	 						

EXAMINER DATE CONSIDERED

Sheet **02** of **02**

Serial No. Docket No. -1449 Modified 09/700,700 DEX-0105 List of Patents and Publications Applicant Cited by Applicant Ali et al. (Use several sheets if necessary) Group Filing Date U.S. Department of Commerce 1642 November 20, 2000 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Abate-Shen et al., "Nkx3.1; Pten Mutant Mice Develop Invasive Prostate Adenocarcinoma and Lymph Node Metastases¹", Cancer Research 2003 63(14):3886-3890 Bierberich et al., "Prostate-specific and Androgen-DB dependent Expression of a Novel Homeobox Gene", J. Biol. Chem. 1996 271(50):31779-31782 reprinted as pages 1-10 He et al., "A Novel Human Prostate-Specific, Androgen-Regulated DC Homeobox Gene (NKX3.1) That Maps to 8p21, a Region Frequently Deleted in Prostate Cancer", Genomics 1997 43:69-77 Herbrand et al., "Transcription factors Nkx3.1 and Nkx3.2 (Bapx1) DDplay an overlapping role in sclerotomal development of the mouse", Mechanisms of Development 2002 117:217-224 Kim et al., "Nkx3.1 Mutant Mice Recapitulate Early DEStages of Prostate Carcinogenesis1", Cancer Research 2002 62:2999-3004 Kim et al., "Cooperativity of Nkx3.1 and Pten loss of function in a DF mouse model of prostate carcinogenesis", Proc. Natl. Acad. Sci. USA 2002 99(5):2884-2889 reprinted as pages 1-10 Prescott et al., "Isolation and Androgen Regulation of DG the Human Homeobox cDNA, NKX3.1", The Prostate 1998 35:71-80 Sciavolino et al., "Tissue-Specific Expression of Murine DH Nkx3.1 in the Male Urogenital System", Developmental Dynamics 1997 209:127-138 NCBI Genbank Accession U80669 [gi:1732377] 10 December DΙ 1996 - 3 June 1999 with Revision History

EXAMINER

APR 0 8 2004

DATE CONSIDERED